$Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study$

Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study

Previously, we reported the efficacy and safety of tazemetostat in Japanese patients with relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) harboring the EZH2 mutation in a multicenter, open-label, phase II study. Here, we present a follow-up analysis of tazemeto...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of hematology 2024-11, Vol.120 (5), p.621-630
Hauptverfasser:	Izutsu, Koji, Ando, Kiyoshi, Nishikori, Momoko, Shibayama, Hirohiko, Goto, Hideki, Kuroda, Junya, Kato, Koji, Imaizumi, Yoshitaka, Nosaka, Kisato, Sakai, Rika, Abe, Maho, Hojo, Seiichiro, Nakanishi, Tadashi, Rai, Shinya
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over B-cell lymphoma Benzamides - therapeutic use Biphenyl Compounds - therapeutic use Clinical Trials, Phase II as Topic Effectiveness Enhancer of Zeste Homolog 2 Protein - genetics Female Follow-Up Studies Hematology Hodgkin's lymphoma Humans Hypogammaglobulinemia Japan Lymphocytes B Lymphoma Lymphoma, Follicular - drug therapy Lymphoma, Follicular - genetics Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - mortality Male Medicine Medicine & Public Health Middle Aged Morpholines - administration & dosage Morpholines - adverse effects Morpholines - therapeutic use Mutation NCT NCT03456726 Neuropathy Oncology Original Original Article Peripheral neuropathy Pyridones - administration & dosage Pyridones - adverse effects Pyridones - therapeutic use Recurrence Treatment Outcome Urinary tract
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!